查看購物車
  • Simplified Chinese
  • English
  • Japanese
醫療事務的評價(美國)- 慢性特發性蕁麻疹
市場調查報告書
商品編碼
1745091

醫療事務的評價(美國)- 慢性特發性蕁麻疹

Medical Affairs Reputations (US) - Chronic Spontaneous Urticaria
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

最近一項針對美國過敏症專家的調查顯示，幾家大型慢性特發性蕁麻疹醫療事務團隊在幾個關鍵領域仍有很長的路要走。我們揭示了醫生們認為自己做得好的方面、他們希望改進的方面以及不滿意的原因。在本報告中，我們揭示了醫療事務如何滿足治療慢性特發性蕁麻疹醫師的高期望。我們比較了幾家領先的慢性特發性蕁麻疹公司醫療事務團隊的當前表現。

關鍵問題

  • 1.醫師與醫療事務團隊的互動頻率為何？這種頻率是在增加還是在減少？
  • 2.醫師目前如何使用醫療事務團隊提供的服務？
  • 3.醫療事務支援的哪些面向對醫師來說最重要？他們對所提供的支援有多滿意？
  • 4.醫師希望與醫療事務團隊進行哪種類型的互動？他們希望這種互動的頻率是多少？
  • 5.醫療事務團隊如何更能滿足醫師的需求？
  • 6.醫療事務團隊在特定品牌的表現是低於還是高於預期？
  • 7.未來您可以如何改善醫療事務服務，以便更好地滿足醫師的需求？
  • 8.競爭對手的醫療事務團隊在哪些方面最弱，哪些方面最強？

領導品牌

  • zorea(Omalizumab)
  • deyupikusento(deyupirumabu)
  • remiburuchinibu
  • baruzoruborimabu

調查手法

FirstView 報告是基於透過 LiMATM 選定的醫生進行的定量調查得出。 LiMATM 是全球最大的醫生名錄，擁有超過 300 萬名已確認的醫生。醫生。每位醫生均根據嚴格的篩選標準精心挑選，以確保收集到的見解具有相關性、可靠性，並反映頂尖醫療專業人士的真實聲音和經驗。研究結果以易於理解的圖表形式呈現，方便您快速消化和分析數據。憑藉 LiMATM 的廣泛覆蓋範圍和精準度，FirstView Reports 提供無與倫比的數據驅動洞察，指導您的策略規劃，並幫助您在快速發展的醫療保健領域保持領先地位。

我們的報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供詳細且可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助您掌握新興趨勢並有效解決複雜課題。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖的獨立、公正的見解，我們的報告可提供您所需的準確性和可靠性。獨家獨家訪談和數據，以及持續的市場監測，讓您全面洞察市場動態。我們的報告涵蓋 40 多個活躍疾病領域，匯集醫生情報（包括 KOL 洞察和定量醫生調查），以及行業專家對醫療事務、數位醫療、銷售與行銷、市場准入及其他領域問題的看法，助您做出更明智的數據驅動決策，在快速變化的行業中保持競爭力。

簡介目錄

According to this latest survey of US allergists, the performance of chronic spontaneous urticaria medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied. This report reveals how medical affairs can better meet the high expectations of physicians treating chronic spontaneous urticaria. It compares the current performance of medical affairs teams for several leading treatments for chronic spontaneous urticaria from various companies.

Key Questions Answered:

  • 1. How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
  • 2. In what ways do physicians currently use the services provided by Medical Affairs teams?
  • 3. What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
  • 4. What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
  • 5. How successful are Medical Affairs teams at meeting physician needs?
  • 6. Are Medical Affairs teams falling short or exceeding goals with any particular brands?
  • 7. How can Medical Affairs services be improved to better meet the needs of physicians in the future?
  • 8. In what areas are your competitors' Medical Affairs teams weakest and strongest?

Key Brands:

  • Xolair (omalizumab)
  • Dupixent (dupilumab)
  • remibrutinib
  • barzolvolimab

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.